Evidence map›Paper›PMID 32484743›Full record

ArticleAIDS patient care and STDs2020

Integrating HIV Pre-Exposure Prophylaxis into Family Planning Care: A RE-AIM Framework Evaluation.

Ashley R Brant, Preeti Dhillon, Shawnika Hull, Megan Coleman, Peggy P Ye, Pamela S Lotke, Jeannie Folan, Rachel K Scott

Open access · greenAbstract read
In one paragraph

Article in AIDS patient care and STDs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Ashley R BrantWomen's Health Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Preeti DhillonAIDS Clinical Trials Group (ACTG) Network Coordinating Center, Social & Scientific Systems, Silver Spring, Maryland, USA.
Shawnika HullMilken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.
Megan ColemanWhitman-Walker Health, Washington, District of Columbia, USA.
Peggy P YeMedStar Washington Hospital Center, Washington, District of Columbia, USA.
Pamela S LotkeMedStar Washington Hospital Center, Washington, District of Columbia, USA.
Jeannie FolanGeorgetown University School of Medicine, Washington, District of Columbia, USA.
Rachel K ScottMedStar Washington Hospital Center, Washington, District of Columbia, USA.
MedStar Washington Hospital Center · USAIDS Clinical Trials Group · USCleveland Clinic · USColorado State University · USGeorgetown University · USMilken Institute · USWhitman-Walker Health · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
Substance Use and HIV Prevention Research in Minority Communities Training ProgramR25DA028567 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Julia Lechuga, Torsten Brian Neilands · 2009 to 2026
$5.4M
NCATS NIH HHS UL1 TR001409NIAID NIH HHS P30 AI094189NIDA NIH HHS R25 DA028567
6 · The paper itself

Abstract

We aimed to systematically evaluate the feasibility of integrating HIV prevention services, including pre-exposure prophylaxis (PrEP), into a family planning setting in a high-prevalence community. We used the RE-AIM Framework (Reach, Efficacy, Adoption, Implementation, Maintenance) to evaluate the integration of HIV prevention services into a family planning clinic over 6 months. Before the integration, PrEP was not offered. We implemented a staff training program on HIV PrEP. We determined the proportion of women presenting to the clinic who were screened, eligible for, and initiated PrEP through chart review. We assessed staff comfort with PrEP pre- and post-integration. We compared planned and actual implementation, interviewed staff to determine barriers and facilitators, and tracked systems adaptations. We assessed maintenance of PrEP after the study concluded. There were 640 clinical encounters for 515 patients; the rate of HIV counseling and PrEP screening was 50%. The rate was 10% in month 1 and peaked to 65% in month 3. Nearly all screened patients were eligible for PrEP (98.4%) and 15 patients (6%) initiated PrEP. Staff knowledge and comfort discussing PrEP improved after education. Facilitators included partnering with local experts, continuing education, clinical tools for providers, and patient education materials. Barriers included competing priorities during clinical encounters, limited woman-centered patient education materials, and insurance-related barriers. Embedding HIV prevention services in the family planning setting was feasible in this pilot. The proportion of women screened for PrEP rapidly increased. In this high HIV prevalence community, nearly all screened women were eligible and 6% initiated PrEP.

Indexed as

AdultAmbulatory Care FacilitiesAnti-HIV AgentsCohort StudiesCounselingDelivery of Health Care, IntegratedFamily Planning ServicesFemaleHIV InfectionsHumansMass ScreeningPre-Exposure ProphylaxisProspective StudiesSex EducationSexual PartnersAnti-HIV Agentsfamily planningHIV preventionimplementationPrEPwomen

Identifiers

PMID32484743
PMCPMC7262643
OpenAlexW3030223824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.